News UK's Oyster Tx rebrands and raises $60m for Alzheimer's R&D UK start-up Oyster Therapeutics has raised $60m in first-round financing for its novel take on protein degraders, starting with tau in Alzheimer's.
R&D Alzheimer's research is moving toward more selective targets As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.
News FDA greenlights Roche’s biomarker blood test for Alzheimer's Roche has won US FDA clearance for a blood test that could move Alzheimer’s biomarker testing further into primary care.
News Tauklarify PET approval for Lantheus in AD NFT pathology The FDA approves Lantheus' Tauklarify radiodiagnostic PET to evaluate NFT pathology in Alzheimer's disease.
News Biogen, Ionis trumpet Alzheimer's data, but shares dip Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, to a mixed response.
News Trial miss doesn't dent Biogen's faith in Alzheimer's drug Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.